PROCEPT BioRobotics CorpPRCT

PROCEPT BioRobotics Corp is losing money faster than a leaky catheter, even though it sells a slick robotic water-jet prostate zapper called Aquablation that the company markets as “advanced BPH treatment for enlarged prostate” and which comes with a touchscreen that looks like it belongs in a lunar lander. The business booked revenue of $83.1 million in the quarter to 31 March 2026 but still managed to lose $31.6 million in net income, while operating cash flow came in at a negative $38.1 million, which is the kind of arithmetic that makes “profitless prosperity” feel like an understatement. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1588978/000162828026042277/xslF345X06/wk-form4_1781124370.xml)

Aquablation therapy is a robot-assisted procedure that uses computer-controlled water jets to trim prostate tissue in a minimally invasive 8-to-10-minute operation; the company claims the technique preserves sexual function better than older methods and works across prostate sizes. The clinical data page cites multiple trials showing low rates of post-operative complications, which is good news for patients but less good for shareholders when the therapy is still being sold at a loss. (source: Aquablation Clinical Data for HCPs | PROCEPT BioRobotics, https://www.procept-biorobotics.com/healthcare-providers/clinical-data)

The balance sheet is a study in contrasts: total assets hit $487.1 million at quarter-end, with $245.6 million in cash and equivalents, while liabilities clocked in at $139.4 million and stockholders’ equity held at $347.7 million. Inventories swelled by $7 million to $77.5 million, and the company spent $2.9 million on capex during the period, a modest figure that still feels high when the top line is barely covering operating costs. Diluted EPS landed at minus $0.56 on 56.5 million shares, which is the accounting equivalent of telling a prostate patient the operation was “very precise” even though the bill is still in collection. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1588978/000162828026042270/xslF345X06/wk-form4_1781124228.xml)

For an operating company whose main product is already in hospitals, the absence of share buybacks is noticeable; the six 10-June-2026 Form 4 filings show insiders transacting options and shares rather than trimming the share count, while the diluted share count stayed flat at 56.5 million across the quarter, implying that buyback cheques are currently being filed under “to do later.” (source: SEC EDGAR Form 4 index, https://www.sec.gov/Archives/edgar/browse/?CIK=1588978)

The company’s investor-relations page promises “resources and support for healthcare providers,” which in practice means glossy brochures and a slick GUI on the AquaBeam console-useful for surgeons, less so for a cash-burning medical-device outfit that still hasn’t managed to turn a GAAP profit. Until the revenue line can consistently exceed the combined weight of operating losses, R&D, and inventory build, the story remains a prototype in search of a sustainable business model. (source: Resources & Support for Healthcare Providers | PROCEPT, https://www.procept-biorobotics.com/healthcare-providers/resources)